111448-52-3

Upstream product

• 50737-52-5 ethyl 2-cyano-3-(4-fluorophenyl)acrylate 
• 460-00-4 1-Bromo-4-fluorobenzene 
• 459-57-4 4-fluorobenzaldehyde 
• 947739-65-3 ethyl 2-cyano-3-(4-fluorophenyl)acrylate 
• 105-56-6 ethyl 2-cyanoacetate 

Downstream Products

• 342-75-6 3,3-bis(4-fluorophenyl)-propanoic acid 
• 80273-37-6 3-{4-[6-Fluoro-3-(4-fluoro-phenyl)-indan-1-yl]-piperazin-1-yl}-propane-1,2-diol 
• 85663-36-1 2-{4-[(1S,3R)-6-Fluoro-3-(4-fluoro-phenyl)-indan-1-yl]-piperazin-1-yl}-propane-1,3-diol 
• 85663-37-2 2-{4-[(1S,3S)-6-Fluoro-3-(4-fluoro-phenyl)-indan-1-yl]-piperazin-1-yl}-propane-1,3-diol 
• 85663-32-7 4-{4-[(1R,3S)-6-Fluoro-3-(4-fluoro-phenyl)-indan-1-yl]-piperazin-1-yl}-butan-1-ol 
• 85663-33-8 4-{4-[(1S,3S)-6-Fluoro-3-(4-fluoro-phenyl)-indan-1-yl]-piperazin-1-yl}-butan-1-ol 
• 85663-31-6 trans-4-<6-fluoro-3-(4-fluorophenyl)indan-1-yl>-1-piperazinepropanol 
• 85680-82-6 cis-4-<6-fluoro-3-(4-fluorophenyl)indan-1-yl>-1-piperazinepropanol 
• 80273-31-0 trans-4-<3-(4-fluorophenyl)-6-fluoro-1-indanyl>-1-piperazineethanol 
• 80273-32-1 2-{4-[(1S,3S)-6-Fluoro-3-(4-fluoro-phenyl)-indan-1-yl]-piperazin-1-yl}-ethanol 
• 85663-24-7 (+)-trans-1-<6-fluoro-3-(4-fluorophenyl)indan-1-yl>-4-methylpiperazine 
• 80273-00-3 cis-1-<6-fluoro-3-(4-fluorophenyl)indan-1-yl>-4-methylpiperazine 
• 85663-13-4 cis-6-fluoro-3-(4-fluorophenyl)indan-1-ol mesylate 
• 344755-05-1 1-chloro-3-(4-fluorophenyl)-6-fluoroindan 

Relevant academic research and scientific papers

Diarylalkyl-substituted alkylamines and medicaments containing them

A compound I STR1 in which R1 is cycloalkyl, alkenyl, cycloalkenyl, phenyl, STR2 where J, L, M, and E are methine or nitrogen and J', L', M', and E' are methylene, carbonyl or imino; R2 is phenyl or phenylalkyl; a is various amine ra

Neuroleptic activity and dopamine-uptake inhibition in 1-piperazino-3-phenylindans

A series of 1-piperazino-3-phenylindans was synthesized and tested for neuroleptic and thymoleptic activity. Neuroleptic activity was found only in trans racemates and was associated with one of the enantiomers only. The potent and long-acting neuroleptic compound trans-4-[3-(4-fluorophenyl)-6-(trifluoromethyl)indan-1-yl]-1-piperazineeth anol (Lu 18-012, tefludazine) was developed by systematic variation of structural components. Thymoleptic activity was optimized, especially with respect to dopamine-uptake inhibition. No geometrical stereoselectivity was found with regard to dopamine-uptake inhibition, but a high enantioselectivity could be demonstrated for both cis and trans racemates. The most potent compounds were 1-piperazino-3-(3,4-dichlorophenyl)indans with IC50 values of about 2 nM for inhibition of dopamine uptake.